C4 Therapeutics Stock

c4therapeutics.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $74MM

C4 Therapeutics ("C4T") is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

Register To Buy and Sell Shares

For more details on financing and valuation for C4 Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access C4 Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like C4 Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Jane Farran Ph.D
Managing Partner
James Bradner MD
Scientific Co-Founder
Andrew Phillips
Chief Executive Officer
Nathanael Gray Ph.D
Co-Founder & Scientific Advisory Board Member
Chris Nasveschuk Ph.D
Vice President, Chemistry
Marc Cohen
Co-Founder & Executive Chairman
Stewart Fisher Ph.D
Chief Scientific Officer
Isabel Chiu Ph.D
Senior Vice President, Strategic Alliances & Product Management
Adam Crystal
Chief Medical Officer

Board Members

Bruce Downey JD
Elena Prokupets Ph.D
Malcolm Salter
Nathanael Gray Ph.D
Ronald Kaiser
Bihua Chen
Cormorant Asset Management
Ken Anderson MD
Miles Stuchin JD
William Scalzulli
The Kraft Family Foundation
Alain Cohen
Cobro Ventures
Jay Eastman Ph.D
EG Capital Group
Marc Cohen
Norman Gretzinger JD
EG Capital Group

Frequently Asked Questions About C4 Therapeutics’ Stock

plusminus
Can you buy C4 Therapeutics’ stock?
C4 Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy C4 Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell C4 Therapeutics’ stock?
Yes, you can sell stock of a private company like C4 Therapeutics. Forge can help you sell your C4 Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is C4 Therapeutics’ stock price?
C4 Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access C4 Therapeutics’ private market stock price with Forge Data.
plusminus
What is C4 Therapeutics’ stock ticker symbol?
C4 Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

C4 Therapeutics Announces the Addition of Ryan B. Corcoran, M.D., Ph.D. to the Scientific Advisory Board
C4 Therapeutics Announces the Addition of Ryan B. Corcoran, M.D., Ph.D. to the Scientific Advisory Board
C4 poaches new CMO after signing $900M clinical development deal with Roche
C4 Therapeutics has hired Adam Crystal, M.D., Ph.D., a senior director at the Novartis Institutes for BioMedical Research, to be its new chief medical officer and help carry its targeted protein degraders closer to the clinic.
Updated on: Feb 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.